ActiveSight lauched this week its inducible nitric oxide synthase, oriNOS, and peroxisome proliferators-activated recptor gamma, or PPAR gamma, “ready to go” protein crystals for drug discovery. The company now has 14 proteins in its portfolio.
iNOS produces large bursts of nitric oxide as part of the immune response. Overproduction of it has been linked to inflammation and autoimmune diseases, ActiveSight said.
PPAR is the target of the glitazone family of drugs and in addition to being a diabetes target, may also play a role in cancer and inflammation.
Thermo Electron has updated its Darwin LIMS for pharmaceutical manufacturing R&D and QA-QC. Darwin 1.1 now features extensive interfacing capabilities, providing tight integration with SAP, and historical data trending and charting functionality.
“The embedded charting and trending for product stability testing allows for real- time data review and rapid reporting,” the company said in a statement. Darwin 1.1 is also optimized now to operate on the Oracle 10g platform.